Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

爱地希 - NMPA Drug Approval Details

Approvals/NMPA/Disitamab Vedotin For Injection

Approved

生物制品

Disitamab Vedotin For Injection

荣昌生物制药（烟台）股份有限公司🇨🇳 National Medical Products Administration

Approval Date: Aug 21, 2023
Approval ID: 8TCfCeBhQR6
Company: 荣昌生物制药（烟台）股份有限公司
Type: 生物制品

Approval Details

Approval Id: 8TCfCeBhQR6
Approval Number: 国药准字S20237006
Generic Name: 注射用维迪西妥单抗
Generic Name En: Disitamab Vedotin For Injection
Trade Name: 爱地希
Drug Type: 生物制品
Dosage Form: 注射剂
Strength: 40mg/支
Reg Date: 2023-08-21
Company Name: 荣昌生物制药（烟台）股份有限公司
Company Address: 中国（山东）自由贸易试验区烟台片区烟台开发区北京中路58号
Production Company Name: 荣昌生物制药（烟台）股份有限公司
Production Company Address: 中国（山东）自由贸易试验区烟台片区烟台开发区北京中路58号
Company Detail Path: /organization/remegen
Production Company Detail Path: /organization/remegen

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Aug 21, 2023

Approval ID

8TCfCeBhQR6

Type

生物制品

Back to NMPA Approvals